Jeffrey D Long1,2, Douglas R Langbehn1,2, Sarah J Tabrizi3, Bernhard G Landwehrmeyer4,5, Jane S Paulsen1,6,7, John Warner4, Cristina Sampaio4,8. 1. Departments of Psychiatry, University of Iowa, Iowa City, Iowa, USA. 2. Departments of Biostatistics, University of Iowa, Iowa City, Iowa, USA. 3. Department of Neurodegenerative Disease, UCL Huntington's Disease Centre, University College London Institute of Neurology, London, United Kingdom. 4. CHDI Management/CHDI Foundation, Princeton, New Jersey, USA. 5. Department of Neurology, University of Ulm, Ulm, Germany. 6. Departments of Psychology, University of Iowa, Iowa City, Iowa, USA. 7. Departments of Neurology, University of Iowa, Iowa City, Iowa, USA. 8. Laboratory of Clinical Pharmacology and Therapeutics, University of Lisbon, Lisbon, Portugal.
Abstract
BACKGROUND: Characterizing progression in Huntington's disease is important for study the natural course and selecting appropriate participants for clinical trials. OBJECTIVES: The aim was to develop a prognostic index for motor diagnosis in Huntington's disease and examine its predictive performance in external observational studies. METHODS: The prediagnosis Neuro-biological Predictors of Huntington's Disease study (N = 945 gene-positive) was used to select a Cox regression model for computing a prognostic index. Cross-validation was used for selecting a model with good internal validity performance using the research sites as natural splits of the data set. Then, the external predictive performance was assessed using prediagnosis data from three additional observational studies, The Cooperative Huntington Observational Research Trial (N = 358), TRACK-HD (N = 118), and REGISTRY (N = 480). RESULTS: Model selection yielded a prognostic index computed as the weighted combination of the UHDRS total motor score, Symbol Digit Modalities Test, baseline age, and cytosine-adenine-guanine expansion. External predictive performance was very good for the first two of the three studies, with the third being a much more progressed cohort than the other studies. The databases were pooled and a final Cox regression model was estimated. The regression coefficients were scaled to produce the prognostic index for Huntington's disease, and a normed version, which is scaled relative to a 10-year 50% probability of motor diagnosis. CONCLUSION: The positive results of this comprehensive validity analysis provide evidence that the prognostic index is generally useful for predicting Huntington's disease progression in terms of risk of future motor diagnosis. The variables for the index are routinely collected in ongoing observational studies and the index can be used to identify cohorts for clinical trial recruitment.
BACKGROUND: Characterizing progression in Huntington's disease is important for study the natural course and selecting appropriate participants for clinical trials. OBJECTIVES: The aim was to develop a prognostic index for motor diagnosis in Huntington's disease and examine its predictive performance in external observational studies. METHODS: The prediagnosis Neuro-biological Predictors of Huntington's Disease study (N = 945 gene-positive) was used to select a Cox regression model for computing a prognostic index. Cross-validation was used for selecting a model with good internal validity performance using the research sites as natural splits of the data set. Then, the external predictive performance was assessed using prediagnosis data from three additional observational studies, The Cooperative Huntington Observational Research Trial (N = 358), TRACK-HD (N = 118), and REGISTRY (N = 480). RESULTS: Model selection yielded a prognostic index computed as the weighted combination of the UHDRS total motor score, Symbol Digit Modalities Test, baseline age, and cytosine-adenine-guanine expansion. External predictive performance was very good for the first two of the three studies, with the third being a much more progressed cohort than the other studies. The databases were pooled and a final Cox regression model was estimated. The regression coefficients were scaled to produce the prognostic index for Huntington's disease, and a normed version, which is scaled relative to a 10-year 50% probability of motor diagnosis. CONCLUSION: The positive results of this comprehensive validity analysis provide evidence that the prognostic index is generally useful for predicting Huntington's disease progression in terms of risk of future motor diagnosis. The variables for the index are routinely collected in ongoing observational studies and the index can be used to identify cohorts for clinical trial recruitment.
Authors: Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen Journal: Mov Disord Date: 2010-11-15 Impact factor: 10.338
Authors: Michael Orth; O J Handley; C Schwenke; S Dunnett; E J Wild; S J Tabrizi; G B Landwehrmeyer Journal: J Neurol Neurosurg Psychiatry Date: 2010-11-19 Impact factor: 10.154
Authors: Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout Journal: Lancet Neurol Date: 2010-12-02 Impact factor: 44.182
Authors: Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner Journal: Arch Neurol Date: 2006-06
Authors: Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout Journal: Lancet Neurol Date: 2009-07-29 Impact factor: 44.182
Authors: J S Paulsen; D R Langbehn; J C Stout; E Aylward; C A Ross; M Nance; M Guttman; S Johnson; M MacDonald; L J Beglinger; K Duff; E Kayson; K Biglan; I Shoulson; D Oakes; M Hayden Journal: J Neurol Neurosurg Psychiatry Date: 2007-12-20 Impact factor: 10.154
Authors: Jeffrey D Long; Jong-Min Lee; Elizabeth H Aylward; Tammy Gillis; Jayalakshmi Srinidhi Mysore; Kawther Abu Elneel; Michael J Chao; Jane S Paulsen; Marcy E MacDonald; James F Gusella Journal: Am J Hum Genet Date: 2018-08-16 Impact factor: 11.025
Authors: Eun Pyo Hong; Marcy E MacDonald; Vanessa C Wheeler; Lesley Jones; Peter Holmans; Michael Orth; Darren G Monckton; Jeffrey D Long; Seung Kwak; James F Gusella; Jong-Min Lee Journal: J Huntingtons Dis Date: 2021
Authors: Georgia M Parkin; Jody Corey-Bloom; Jeffrey D Long; Chase Snell; Haileigh Smith; Elizabeth A Thomas Journal: Parkinsonism Relat Disord Date: 2022-03-04 Impact factor: 4.402
Authors: Jong-Min Lee; Yuan Huang; Michael Orth; Tammy Gillis; Jacqueline Siciliano; Eunpyo Hong; Jayalakshmi Srinidhi Mysore; Diane Lucente; Vanessa C Wheeler; Ihn Sik Seong; Zachariah L McLean; James A Mills; Branduff McAllister; Sergey V Lobanov; Thomas H Massey; Marc Ciosi; G Bernhard Landwehrmeyer; Jane S Paulsen; E Ray Dorsey; Ira Shoulson; Cristina Sampaio; Darren G Monckton; Seung Kwak; Peter Holmans; Lesley Jones; Marcy E MacDonald; Jeffrey D Long; James F Gusella Journal: Am J Hum Genet Date: 2022-03-23 Impact factor: 11.043
Authors: Alexander L Symonds; Antonella Macerollo; Kevin Foy; Sundus H Alusi; Rhys Davies Journal: Int J Environ Res Public Health Date: 2021-05-12 Impact factor: 3.390